BridegeBio Pharma identifies and improves medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Co.'s pipeline are: Acoramidis/AG10/BBP-265, a small molecule transthyretin (TTR) stabilizer for the treatment of TTR amyloidosis; Infigratinib/BBP-831, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of achondroplasia; BBP-631, a preclinical adeno-associated virus gene transfer for the treatment of congenital adrenal hyperplasia; and Encaleret, a small molecule antagonist of the calcium sensing receptor for the treatment of Autosomal Dominant Hypocalcemia Type 1. The BBIO stock yearly return is shown above.
The yearly return on the BBIO stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the BBIO annual return calculation with any dividends reinvested as applicable (on ex-dates).
|